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Abstract
Background: Hyperhomocysteinemia is a well recognised risk factor 
for arterial and venous thrombosis. The most common form results 
from methylenetetrahydrofolate reductase (MTHFR) gene mutations 
leading to decreased enzymatic activity.
Case report: We present the case of a 34 year-old woman with a 
sudden onset of left hemiparesis and aphasia accompanied by retros-
ternal pain. She is diagnosed with acute posteroinferolateral myocar-
dial infarction and stroke. Homocysteine level was determined and it 
was moderately elevated. The coronary angiogram revealed partially 
recanalised embolic occlusion of posterior left ventricular branch and 
posterior interventricular artery. A conservative treatment manage-
ment is adopted. She remained haemodynamically stable, with com-
plete resolution of neurological symptoms and evolution to subacute 
myocardial infarction.
Conclusions: The particularity of our case is represented by symul-
taneous thromboembolic events causing myocardial infarction and 
ischemic stroke in a patient with a history of recurrent pregnancy 
loss, which was previously diagnosed with MTHFR gene mutation. 
Moderate hyperhomocysteinemia, also found in our patient, is re-
cognised as an ethiopathogenic factor of thrombophilia. The right 
diagnosis and therapeutic approach could be the key to improved 
prognosis in this category of patients. MTHFR gene mutation cau-
sing hyperhomocysteinemia should be suspected in patients with 
thromboembolic events, especially when occuring repeatedly or at 
young ages.
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Introduction
Thrombophilias are conditions associated with hy-
percoagulable status and increased risk of arterial 
and venous thrombosis, which represents a signi-
ficant cause of mortality and morbidity worldwide 
[1]. The prothrombotic states may be inherited or 
acquired, but also due to genetic and environmental 
interactions [2]. Investigating for thrombophilia re-
quires an initial evaluation of classical prothrombotic 
risk factors such as smoking, dyslipidemias, arterial 
hypertension or diabetes mellitus. Extended profile 
of investigations is necessary in patients with arte-
rial or venous thrombosis which occur repeateadly, 
in unusual sites or at young ages, when family 
aggregation of thrombotic events is identified, as 
well as in women with recurrent idiopathic preg-
nancy loss. It must include a complete blood count 
and erythrocyte sedimentation rate, a blood film 
examination, prothrombin time (PT) and activated 
partial thromboplastin time (aPTT), factor V Leiden, 
antithrombin and fibrinogen levels, protein C and 
S, prothrombin gene mutations, homocysteinemia, 
methylenetetrahydrofolate reductase (MTHFR) gene 
mutations and antiphospholipid antibodies [3].
Homocysteine has been recognised as a cardio-
vascular risk factor besides the traditional ones such 
as smoking, obesity, diabetes mellitus and arterial 
hypertension, in line with the observations made in 
patients with homocystinuria [4-6]. This is an inborn 
error of methionine metabolism caused by deficient 
activity of cysthationine β-synthase (CBS) and the-
reby impairment of the transsulphuration pathway 
leading to excessive accumulation of homocysteine 
[7, 8]. Numerous studies have demostrated the early 
onset and rapid development of arteriosclerosis in 
patients with homocystinuria. Moreover, thromboe-
mbolic events, both arterial and venous have been 
reported, which represent the main life threatening 
complication at young ages [4, 8-11].
Experimental data suggested the mechanisms res-
ponsible for atherogenic and thrombogenic effects 
of high homocysteine levels: induces oxidative stress 
and vascular inflammation, promotes endotelial 
dysfunction as a result of increased asymmetric di-
methylarginine (ADMA), an endogenous inhibitor of 
NO-syntase, reduces bioavailability of nitric oxide, 
alters lipoprotein metabolism, produces vascular hy-
pertrophy in the microcirculation, stimulates tissue 
factor expression in monocytes, increases platelet 
aggregation and interferes with several clotting fac-
tors [12-16]. A new study demonstrated that hyper-
homocysteinemia exacerbates vascular constrictive 
remodelling after arterial balloon injury by accelera-
ted neointima formation and collagen accumulation 
in the adventitia [17].
Homocysteine concentrations are determined by 
synergistic action of genetic and nutritional factors 
such as serum folate, riboflavin and cobalamin [18-
20]. It appears to be also influenced by physiological 
factors (dietary habits, male sex, menopause, alco-
hol and coffee intake, smoking, increased muscle 
mass), diseases (reduced glomerular filtration rate 
and overt renal failure, hypothyroidism, diabetes 
mellitus, psoriasis) and drugs [16, 20].
Methylenetetrahydrofolate reductase (MTHFR) 
is involved in homocysteine metabolism and ca-
talyzes the conversion of 5,10-methylenetetrahy-
drofolate (5,10 MTHF) to 5-methyltetrahydrofolate. 
This serves as a methyl donor in the subsequent 
homocysteine remethylation to methionine, reac-
tion catalyzed by methionine synthase (MS) and 
requiring cobalamin as a cofactor [21]. It is also 
acknowledged that MTHFR plays a role in distri-
buting folate species either towards homocysteine 
remthylation as depicted above, or to nucleic acids 
biosynthesis [21, 22]. Two common MTHFR gene 
polymorphisms have been identified: C677T and 
A1298C. C677T polymorphism results from C→T 
transition at nucleotide 677 in exon 4 and produ-
ces an alanine to valine amino acid substitution in 
the biomolecular structure [23, 24]. The incidence 
of homozygous mutation (TT) in general popula-
tion varies between 5 and 12% [25-28]. The hete-
rozygous mutation has an incindence of 25-40% 
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[29]. The C677T mutation produces a thermolabile 
variant of the enzyme characterized by decreased 
catalytic activity and hyperhomocysteinemia. In 
comparison with the wild type allele, the residual 
enzyme activity is as low as 30 to 50% in homo-
zygotes and 65% in heterozygotes [30-32].
Case report
We present the case of a female patient from ur-
ban environment, aged 34, with a remote smoking 
history of 5 pack-years, who reported no drinking 
or drug use and without significant family history. 
The patient's medical history was notable for obs-
tetrical events consisting of two pregnancies (at age 
29 and 31) that ended at an unknown gestational 
age and the reason was not determined. Eighteen 
months ago she had a stillbirth occuring in a full-
term pregnancy. Shortly after she was tested for 
thrombophilia and the heterozygous C677T muta-
tion of MTHFR gene was discovered. At the time 
treatment with aspirin, folic acid and omega 3 fatty 
acids was recommended, but the patient interrup-
ted it after two months.
The patient had been well until the day of ad-
mission, when she reported sudden onset of left 
hemiparesis and motor aphasia, strongly suggesti-
ve of right hemisphere stroke. Non-contrast com-
puted tomography was performed within 2 hours 
from presentation and showed no images consis-
tent with intracerebral infarction or hemorrhage. 
Shortly after the investigation and before starting 
anticoagulant therapy the patient reported sudden 
development of retrosternal pain of medium in-
tensity, occuring at rest and lasting longer than 
30 minutes. The electrocardiogram showed ST 
segment elevation and Q waves in inferior leads 
and correlated with raised myocardial biomarkers 
(creatine-kinase MB 166 u/L, TroponinT 7.72 ng/
mL, ASAT 288 u/L, LDH 1438U/L). She was refe-
rred to a cardiologist.
 On examination the patient is haemodynamica-
lly stable, blood pressure (BP) 120/70mmHg at both 
arms, heart rate (HR) 80, rhythmic heart sounds 
without additional murmurs and normal oxygen 
saturation. The neurological examination revealed 
minimal motor deficit, paresthesia and weakness 
of the left arm and no aphasia. The ECG aspect is 
consistent with the diagnosis of acute posteroin-
ferolateral myocardial infarction with ST segment 
elevation (Fig.1). Ecocardiography revealed undi-
lated left ventricle with preserved global systolic 
function, with an ejection fraction of 50%, normal 
contractility except for akinesia of the mediobasal 
segment of the inferior wall. There are no signs 
of pericardial effusion, intracavitary thrombi, atrial 
dilation, diastolic dysfunction, valvular disease or 
pulmonary hypertension and the right ventricle is 
normal.
Figure 1:  Acute posteroinferolateral ST elevation myocardial infarction.
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The patient underwent emergency coronary 
angiography for non–ST-segment elevation myo-
cardial infarction which revealed partially recanali-
sed embolic occlusion of posterior left ventricular 
branch and posterior interventricular artery (Fig.2). 
A conservative treatment strategy is adopted and 
anticoagulant therapy with unfractioned heparin is 
immediately started. Dual antiplatelet therapy (aspi-
rin plus clopidogrel) and high-dose statin (atorvas-
tatin) are associated. Spironolactone is added later 
on and is preferred as anti-remodelling agent due 
to low blood pressure values. 
Figure 2:  Partially recanalised embolic occlusion 
of posterior left ventricular branch and 
posterior interventricular artery.
A new computed tomography of the brain is per-
formed in the fifth day after admission. It revealed 
a cortico-subcortical hypodense area, 40/29mm, 
located in the temporo-parietal right hemisphere, 
suggestive of subacute ischemic stroke.
Further testing for thrombophilia was recommen-
ded in order to rule out causes of acquired prothrom-
botic states. The titres of antinuclear antibodies and 
their subsets, as well as antiphospholipid antibodies 
were within the normal range. Homocysteine plas-
ma concentration has also been determined and it 
was moderately raised (32 μmol/L). 
Under treatment she remained haemodynamica-
lly stable, experienced no recurrent anginal pain and 
had a complete resolution of neurological symp-
toms within three days from admission. Repeated 
ECG showed evolution to subacute myocardial in-
farction aspect and transthoracic echocardiogram 
at discharge revealed a slight improvement of in-
ferior wall contractility with residual hipokinesis of 
the medio-basal segment. The patient is dischar-
ged home after 12 days of hospitalization with the 
main diagnosis of acute posteroinferolateral myo-
cardial infarction with conservative treatment and 
acute temporo-parietal ischemic stroke, both due 
to thromboembolic events in the context of throm-
bophilia. 
Discussion
The mechanism by which MTHFR gene mutations 
produce prothrombotic states is represented by 
eleveted levels of plasma homocysteine due to de-
creasd enzymatic activity of methylenetetrahydro-
folate reductase. This effect is amplified by all the 
above mentioned factors, especially low concen-
trations of serum folate and vitamins B complex. 
However, data from literature are inconsistent and 
insufficient.
Numerous studies have demonstrated an in-
crease in cardiovascular risk in the presence of ele-
vated levels of homocysteine [30-35]. Discordant 
results have been found in prospective studies, 
some of them showing strong associations and 
some of them none [35]. A meta-analysis of 30 
prospective and retrospective studies showed that 
25% lower homocysteine levels was associated 
with 11% lower ischemic heart disease risk and 
19% lower stroke risk, suggesting an indepen-
dent role of homocysteine as a cardiovascular risk 
factor, albeit modest [36]. Another meta-analysis 
demonstrated a weak, but significant association 
between homocysteinemia and coronary heart di-
sease risk in prospective studies and a more robust 
association when correlated with cerebrovascular 
disease [37].
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Data drom literature indicate the association 
between moderately raised homocysteinemia and 
atherothrombosis risk, nevertheless in our patient 
no underlying atherosclerotic lesions have been 
found, pointing out a thromboembolic mechanism, 
both for stroke and myocardial infarction.
Medical data strongly affirm the association of 
severe hyperhomocysteinemia with high cardio-
vascular risk. However, regarding moderate or 
mild elevations in homocysteine levels, determi-
ned most frequently by MTHFR gene mutations, 
the results of the studies are discordant [38-46]. 
In this case, simultaneous ischemic events occu-
red in a patient with no overt classical risk fac-
tors. Although moderately elevated, hyperhomo-
cysteinemia due to MTHFR mutation, previously 
identified in this patient, has been responsible for 
concurrent thromboembolic stroke and myocar-
dial infarction.
There is debate about the existence of a real 
causal relationship between hyperhomocystei-
nemia per se and the cardiovascular outcomes. 
Although most of the studies demonstrate the 
association, little evidence is available to support 
the direct causality, relationship [44, 47, 48]. Al-
beit several pathogenic effects of hyperhomo-
cysteinemia have been evidenced, the following 
uncertainties emerged: is hyperhomocysteinemia 
merely associated with classical risk factors like 
smoking, dyslipidemias, arterial hypertension, thus 
creating confusion regarding its independent role 
in atherogenesis and thrombogenesis; is hyperho-
mocysteinemia an effect of atherosclerosis and/or 
acute vascular events rather than a causative agent 
[47-50]; the existence of subclinical premature re-
nal impairment in atherosclerosis patients, thereby 
affecting homocysteine clearance [47, 49, 51]. The-
refore it has been postulated that homocysteine 
is at most a marker of cardiovascular risk rather 
than an ethiological factor. Studying the correla-
tion between MTHFR genotypes and cardiovascu-
lar risk has been proposed in order to demonstrate 
that a cause of chronic hyperhomocysteinemia is 
associated implicitly with high cardiovascular risk, 
therefore supporting the direct causality relation-
ship [44, 47].
MTHFR gene mutation carriers have a decrea-
sed enzymatic activity and higher levels of ho-
mocysteine which are inversely related to fola-
te status. A meta-analysis including 40 studies, 
both retrospective and prospective, demonstrated 
a 16% higher risk of developing coronary heart 
disease in patients with MTHFR 677TT genotype 
and a trend toward increased risk in heterozygous 
patients (CT genotype) compared the normal ge-
notype (CC). It also showed that the risk is high 
only in patients with low folate status [44]. Signi-
ficant higher risk of ischemic heart disease, deep 
vein thrombosis and stroke associated with MTH-
FR-TT genotype has been found in another meta-
analysis including 92 studies, concluding that this 
correlation provides evidence for direct causality 
between hyperhomocysteinemia and cardiovas-
cular disease [38].
Recurrent pregnancy loss represents a health 
issue affecting up to 5% of women of repro-
ductive age [52]. The ethiological factors include 
uterine anomalies, endocrinologic disorders such 
as hypothyroidism, chromosomial or immunologic 
abnormalities and infectious diseases [53-55]. After 
ruling out the above mentioned factors, throm-
bophilia may be the underlying pathology in wo-
men with recurrent miscarriages [54, 55]. Adverse 
pregnancy outcomes reportedly associated with 
thrombophilia are preeclampsia, abruptio placen-
tae, IUGR-intrauterine growth restriction, IUFD-
intrauterine fetal demise and stillbirth [56]. There 
is debate as to whether MTHFR mutations are as-
sociated with pregnancy complications and data 
are inconsistent. Placental vasculopathy, seemingly 
determined by hyperhomocysteinemia, has been 
proposed as ethiopathogenic mechanism [57]. The 
term encompasses the abnormal placental findings 
at anatomopathological examination and develop 
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as a result of endotelial dysfunction, vasoconstric-
tion, hypercoagulability and thrombosis, placentar 
ischaemia and infarction, all leading to impaired 
placentar perfusion and compromising the ma-
terno-fetal circulation [58-61]. Our patient has a 
history of three pregnacy losses, including stillbir-
th, without any identified cause except for MTH-
FR gene mutation causing hyperhomocysteinemia 
and prothrombotic state, which was not reversed 
by anticoagulant therapy during pregnancy. 
Conclusions
The particularity of the presented case is the oc-
curance of two simultaneous thromboembolic 
events, coronary and cerebrovascular, in the pre-
sence of moderate hyperhomocysteinemia most 
likely due to MTHFR gene mutation. This adds to 
the evidence pleeding for significant association 
of hyperhomocysteinemia with prothrombotic sta-
te leading to increased cardiovascular risk. MTHFR 
gene mutations, as the main causes of moderate 
high levels of homocysteine, should be suspected 
in patients with thromboembolic events and no 
classical risk factors. Recurrent pregnancy loss is 
another manifestation of thrombophilia caused 
by hyperhomocysteinemia and MTHFR gene mu-
tations. Correct and timely diagnosis of throm-
bophilia in patients with a first embolic event or 
pregnancy loss, followed by adequate therapeutic 
management could result in improved prognosis 
for this category of patients.
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